Awstralja - Ingliż - APVMA (Australian Pesticides and Veterinary Medicines Authority)

adama australia pty limited - alpha-cypermethrin; liquid hydrocarbon - ultra low volume - alpha-cypermethrin pyrethroid active 16.0 g/l; liquid hydrocarbon solvent other 871.0 g/l - insecticide - broccoli | brussels sprouts | cabbage | canola | cauliflower | chinese cabbage | cotton | eucalyptus plantation | field pea | gr - aphids - rhopalosiphum spp. | blackheaded pasture cockchafer | blue oat or pea mite | brown pasture looper | cabbage moth | cabbage white butterfly | cluster caterpillar | common armyworm - mythimna convecta | corn earworm | cotton budworm or bollworm | cutworm - agrotis spp. | green mirid bug | grey cluster bug | helicoverpa armigera | native budworm or bollworm | pea weevil | plague thrips | redlegged earth mite | rough bollworm | rutherglen bug | sorghum midge | southern or barley armyworm | tasmanian eucalyptus leaf beetle | tobacco looper or looper caterpillar | tomato grub | vegetable weevil | wingless grasshopper | acrossidius tasmaniae | barley armyworm | barley grub | barley yellow dwarf virus vect | bollworm | corn earworm | cotton bollworm | desiantha weevil (wa) | diamondback moth | heliothis | leucania convecta | native bollworm | red legged earth mite | southern armyworm | tobacco budworm | tomato grub

Awstralja - Ingliż - APVMA (Australian Pesticides and Veterinary Medicines Authority)

titan ag pty ltd - alpha-cypermethrin - suspension concentrate - alpha-cypermethrin pyrethroid active 250.0 g/l - insecticide

Awstralja - Ingliż - APVMA (Australian Pesticides and Veterinary Medicines Authority)

ezycrop pty ltd - alpha-cypermethrin; liquid hydrocarbon - emulsifiable concentrate - alpha-cypermethrin pyrethroid active 100.0 g/l; liquid hydrocarbon solvent other 735.0 g/l - insecticide

Awstralja - Ingliż - APVMA (Australian Pesticides and Veterinary Medicines Authority)

elders rural services australia limited - alpha-cypermethrin; hydrocarbon liquid - emulsifiable concentrate - alpha-cypermethrin pyrethroid active 100.0 g/l; hydrocarbon liquid solvent other 760.0 g/l - insecticide

Stati Uniti - Ingliż - NLM (National Library of Medicine)

takeda pharmaceuticals america, inc. - .alpha.1-proteinase inhibitor human (unii: f43i396ois) (.alpha.1-proteinase inhibitor human - unii:f43i396ois) - .alpha.1-proteinase inhibitor human 1 g in 50 ml - glassia is an alpha1 -proteinase inhibitor (human), indicated for chronic augmentation and maintenance therapy in individuals with clinically evident emphysema due to severe hereditary deficiency of alpha1 -pi, also known as alpha1 -antitrypsin (aat) deficiency. limitations of use : - the effect of augmentation therapy with glassia or any alpha1 -pi product on pulmonary exacerbations and on the progression of emphysema in alpha1 -pi deficiency has not been conclusively demonstrated in randomized, controlled clinical trials. - clinical data demonstrating the long-term effects of chronic augmentation and maintenance therapy of individuals with glassia are not available. - glassia is not indicated as therapy for lung disease in patients in whom severe alpha1 -pi deficiency has not been established. glassia is contraindicated in: - immunoglobulin a (iga) deficient patients with antibodies against iga. - individuals with a history of anaphylaxis or other severe systemic reaction to alpha1 -pi products. risk summar

Ingilterra - Ingliż - MHRA (Medicines & Healthcare Products Regulatory Agency)

alliance pharmaceuticals ltd - alpha tocopheryl acetate - oral suspension - 100mg/1ml

Stati Uniti - Ingliż - NLM (National Library of Medicine)

grifols usa, llc - .alpha.1-proteinase inhibitor human (unii: f43i396ois) (.alpha.1-proteinase inhibitor human - unii:f43i396ois) - .alpha.1-proteinase inhibitor human 1000 mg in 20 ml - prolastin® -c liquid is an alpha1 -proteinase inhibitor (human) (alpha1 -pi) indicated for chronic augmentation and maintenance therapy in adults with clinical evidence of emphysema due to severe hereditary deficiency of alpha1 -pi (alpha1 -antitrypsin deficiency). limitations of use - the effect of augmentation therapy with any alpha1 -pi, including prolastin-c liquid, on pulmonary exacerbations and on the progression of emphysema in alpha1 -pi deficiency has not been conclusively demonstrated in randomized, controlled clinical trials.    - clinical data demonstrating the long-term effects of chronic augmentation or maintenance therapy with prolastin-c liquid are not available. - prolastin-c liquid is not indicated as therapy for lung disease in patients in whom severe alpha1 -pi deficiency has not been established. prolastin-c liquid is contraindicated in: - iga deficient patients with antibodies against iga, due to the risk of severe hypersensitivity. - patients with a history of anaphylaxis or other sever

Awstralja - Ingliż - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - amoxycillin trihydrate -

Awstralja - Ingliż - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - hydralazine hydrochloride -

Awstralja - Ingliż - APVMA (Australian Pesticides and Veterinary Medicines Authority)

alpha crop protection pty ltd - 2,4-d present as the dimethylamine and diethanolamine sa - aqueous concentrate - 2,4-d present as the dimethylamine and diethanolamine sa phenoxy acids-2,4-d active 625.0 g/l - herbicide